

Adult CIRB - Late Phase Emphasis Meeting Agenda

September 17, 2026

I Amendment

EA3231, A Randomized Phase III Study of BRAF-Targeted Therapy vs Cabozantinib in RAI-Refractory Differentiated Thyroid Cancer with BRAF V600Em (Version Date 08/14/26)

II Amendment

NRG-GU013, The Phase III "High Five Trial" Five Fraction Radiation for High-Risk Prostate Cancer (Version Date 08/31/26)

III Continuing Review

A021806, A Phase III Trial of Perioperative versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer (Version Date 07/15/26)

IV Continuing Review

S1931, Phase III Trial Of Immunotherapy-Based Combination Therapy With Or Without Cytoreductive Nephrectomy For Metastatic Renal Cell Carcinoma (Probe Trial) (Version Date 01/06/26)

V Continuing Review

AMC-112, Axicabtagene Ciloleucel in Relapsed or Refractory HIV-Associated Aggressive B-Cell Non-Hodgkin Lymphoma (Version Date 06/18/26)

VI Continuing Review

EA2192, APOLLO: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation (Version Date 11/07/25)

VII Continuing Review

EA5221, A Randomized Phase III Trial of Chemo Immunotherapy vs Immunotherapy Alone for the Vulnerable Older Adult with Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study (Version Date 08/21/26)

VIII Continuing Review

EAF223, Phase II Glioblastoma Accelerated Biomarkers Learning Environment Trial (GABLE) (Version Date 07/03/25)

IX Continuing Review

NRG-GY005, A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS) (Version Date 01/30/26)

X Continuing Review

NRG-GY035, A Randomized Phase III Trial of Carboplatin, Paclitaxel, Pembrolizumab versus Carboplatin, Paclitaxel, Bevacizumab versus Carboplatin, Paclitaxel, Pembrolizumab, Bevacizumab in the Treatment of pMMR, TP53 Mutated Advanced or Recurrent Endometrial Cancer (Version Date 08/04/26)

XI Continuing Review

A092205, Randomized Phase III Trial of Pembrolizumab vs. Pembrolizumab/Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Platinum Refractory Disease (Version Date 08/20/26)

XII Continuing Review

NRG-HN006, Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer (Version Date 04/20/26)

XIII Continuing Review

NRG-HN015, A Phase II Randomized Trial of NEOadjuvant ChemotheraPy or ChemO-Immunotherapy in Patients with Recurrent/Persistent PD-L1 EnrIched Squamous Cell Carcinoma of the Head and Neck Undergoing Salvage Surgery (NEOPOLIS) (Version Date 08/05/26)
